Pardes Biosciences Patents

Patent portfolio assigned to Pardes Biosciences (verified via public assignee records). Estimated patent count: 1. Clinical-stage biopharma (oral SARS-CoV-2 Mpro/3CL protease inhibitor pomotrelvir/PBI-0451). HAS_PATENTS confirmed: US 11,124,497 'Inhibitors of cysteine proteases', assignee Pardes Biosciences, Inc. (granted 2021-09-21; company-announced as its FIRST US patent). patent_count_estimate=1 is conservative (Google Patents assignee search rate-limited); likely more applications exist. Company wound down COVID program in 2023. Pharma has no end-customers; competitors are other COVID antiviral developers.